BTIG analyst Ryan Zimmerman raised the firm’s price target on Carlsmed (CARL) to $24 from $21 and keeps a Buy rating on the shares after its Q3 earnings beat. The company’s top-line outperformance came from increased surgeon growth coupled with steady productivity of 1.9 units/surgeon, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARL: